Par Drugs and Chemicals (NSE:PAR) Piotroski F-Score: 5 (As of Jun. 27, 2026) — 38% Below Median


NSE:PAR Par Drugs and Chemicals Ltd NSE:PAR
74 GF Score
Price ₹91.00
GF Value ₹207.62
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Par Drugs and Chemicals Piotroski F-Score?

Par Drugs and Chemicals NSE:PAR -1.80% 74 Piotroski F-Score is 5 as of Jun. 27, 2026, which is 38% below its 10-year median of 8.00. GuruFocus rates NSE:PAR with a GF Score™ of 74/100 and a GF Value™ of ₹207.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Par Drugs and Chemicals ranks better than 61.37% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Par Drugs and Chemicals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Par Drugs and Chemicals's Piotroski F-Score or its related term are showing as below:

NSE:PAR' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 8   Max: 8
Current: 5

During the past 10 years, the highest Piotroski F-Score of Par Drugs and Chemicals was 8. The lowest was 5. And the median was 8.

Par Drugs and Chemicals  (NSE:PAR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Par Drugs and Chemicals Piotroski F-Score Related Terms


Par Drugs and Chemicals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Par Drugs and Chemicals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Par Drugs and Chemicals Piotroski F-Score Chart

Par Drugs and Chemicals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 8.00 8.00 6.00 5.00

Par Drugs and Chemicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 0.00 0.00 0.00 5.00

NSE:PAR vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Par Drugs and Chemicals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Par Drugs and Chemicals Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Par Drugs and Chemicals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Par Drugs and Chemicals's Piotroski F-Score falls into.


NSE:PAR
74GF Score
Par Drugs and Chemicals Ltd NSE:PAR
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹131 Mil.
Cash Flow from Operations was ₹164 Mil.
Revenue was ₹1,037 Mil.
Gross Profit was ₹603 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (1193.901 + 1292.123) / 2 = ₹1243.012 Mil.
Total Assets at the begining of this year (Mar25) was ₹1,194 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹643 Mil.
Total Current Liabilities was ₹137 Mil.
Net Income was ₹134 Mil.

Revenue was ₹1,010 Mil.
Gross Profit was ₹628 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (1016.111 + 1193.901) / 2 = ₹1105.006 Mil.
Total Assets at the begining of last year (Mar24) was ₹1,016 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹549 Mil.
Total Current Liabilities was ₹166 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Par Drugs and Chemicals's current Net Income (TTM) was 131. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Par Drugs and Chemicals's current Cash Flow from Operations (TTM) was 164. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=131.086/1193.901
=0.10979637

ROA (Last Year)=Net Income/Total Assets (Mar24)
=133.579/1016.111
=0.13146103

Par Drugs and Chemicals's return on assets of this year was 0.10979637. Par Drugs and Chemicals's return on assets of last year was 0.13146103. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Par Drugs and Chemicals's current Net Income (TTM) was 131. Par Drugs and Chemicals's current Cash Flow from Operations (TTM) was 164. ==> 164 > 131 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/1243.012
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/1105.006
=0

Par Drugs and Chemicals's gearing of this year was 0. Par Drugs and Chemicals's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=643.259/137.436
=4.6804258

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=548.61/165.685
=3.31116275

Par Drugs and Chemicals's current ratio of this year was 4.6804258. Par Drugs and Chemicals's current ratio of last year was 3.31116275. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Par Drugs and Chemicals's number of shares in issue this year was 12.309. Par Drugs and Chemicals's number of shares in issue last year was 12.3. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=602.942/1036.556
=0.58167817

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=628.432/1009.735
=0.6223732

Par Drugs and Chemicals's gross margin of this year was 0.58167817. Par Drugs and Chemicals's gross margin of last year was 0.6223732. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1036.556/1193.901
=0.86820934

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1009.735/1016.111
=0.99372509

Par Drugs and Chemicals's asset turnover of this year was 0.86820934. Par Drugs and Chemicals's asset turnover of last year was 0.99372509. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Par Drugs and Chemicals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Par Drugs and Chemicals (NSE:PAR) has a Piotroski F-Score of 5 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Par Drugs and Chemicals and its competitors. This is 38% below median its historical median of 8.00. Over the past decade, Par Drugs and Chemicals' Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, Par Drugs and Chemicals ranks #379 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Par Drugs and Chemicals' Piotroski F-Score too high?
Par Drugs and Chemicals' current Piotroski F-Score of 5 is 38% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Par Drugs and Chemicals' value of 5 is 0% at this industry median. Based on the distribution chart, Par Drugs and Chemicals ranks #379 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Par Drugs and Chemicals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Par Drugs and Chemicals' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Par Drugs and Chemicals ranks #379 out of 981 companies for Piotroski F-Score. This puts Par Drugs and Chemicals in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Par Drugs and Chemicals' value of 5 is 0% at this benchmark. Historically, Par Drugs and Chemicals' own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 5.00, Par Drugs and Chemicals has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Par Drugs and Chemicals's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Par Drugs and Chemicals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Par Drugs and Chemicals's current Piotroski F-Score is 5, which is 38% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Par Drugs and Chemicals stock overvalued right now?
Based on GuruFocus' analysis, Par Drugs and Chemicals (NSE:PAR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹207.62, compared to a current price of ₹91.00 — trading 56.2% below its estimated fair value. The current Piotroski F-Score is 5, which is 38% below median its 10-year median of 8.00 and 0% at the Drug Manufacturers industry median of 5.00. Par Drugs and Chemicals' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Par Drugs and Chemicals (NSE:PAR), the current Piotroski F-Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Par Drugs and Chemicals (NSE:PAR) Overvalued in 2026?

Based on GuruFocus' analysis, Par Drugs and Chemicals stock appears to be undervalued. The current stock price of ₹91.00 is trading 56.2% below its estimated GF Value™ of ₹207.62. GuruFocus considers Par Drugs and Chemicals to be Significantly Undervalued.

Key valuation signals for NSE:PAR:

  • Piotroski F-Score: 5 (38% below median its 10-year median of 8.00)
  • GF Value™: ₹207.62 vs. price of ₹91.00 (56.2% below fair value)
  • GF Score™: 74/100 with 2 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#379 of 981)

No single metric tells the full story. See the NSE:PAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Par Drugs and Chemicals Business Description

Address Gotri Vasna Road, 815, Nilamber Triumph, Vadodara, GJ, IND, 390007
Par Drugs and Chemicals Ltd manufactures active Pharmaceutical Ingredients (APIs) and fine chemicals, serving domestic and international markets. Specializing in essential magnesium-based compounds and other specialty chemicals such as Magnesium Hydroxide, Magnesium Trisilicate, Magnesium Carbonate, various grades of Magnesium Oxide, Dried Aluminum Hydroxide Gel, and Sucralfate USP, the Company produces high-quality bulk drugs used in the formulation of finished pharmaceutical products like tablets, capsules, and liquids. Committed to maintaining stringent quality standards and utilizing manufacturing processes, the Company plays a vital role in supplying reliable ingredients that ensure the safety, efficacy, and stability of pharmaceutical formulations internationally.
74GF Score

Get the complete analysis for NSE:PAR

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.00
Price
₹207.62
GF Value